百花医药
(600721)
| 流通市值：30.46亿 | | | 总市值：30.46亿 |
| 流通股本：3.85亿 | | | 总股本：3.85亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 67,182,856.85 | 388,319,392.98 | 298,606,173.49 | 202,086,632.21 |
| 营业收入 | 67,182,856.85 | 388,319,392.98 | 298,606,173.49 | 202,086,632.21 |
| 二、营业总成本 | 55,423,758.66 | 310,478,518.94 | 225,319,472.13 | 151,013,949.71 |
| 营业成本 | 34,924,216.13 | 211,520,152.12 | 151,815,043.58 | 102,255,288.25 |
| 税金及附加 | 1,401,599.99 | 5,125,162.9 | 3,682,947.99 | 2,458,486.14 |
| 销售费用 | 1,988,608.41 | 12,028,694.33 | 10,113,891.22 | 6,667,951.75 |
| 管理费用 | 13,221,351.4 | 58,457,007.52 | 42,443,518.83 | 28,027,840.35 |
| 研发费用 | 4,028,059.79 | 24,380,901.15 | 18,076,939.87 | 12,168,211.14 |
| 财务费用 | -140,077.06 | -1,033,399.08 | -812,869.36 | -563,827.92 |
| 其中:利息费用 | 79,787.78 | - | - | - |
| 其中:利息收入 | 233,926.83 | 1,113,963.44 | 855,946.7 | 593,081.39 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -19,089.87 | -737,018.3 | - | - |
| 加:投资收益 | 857,955.47 | -6,559,392.6 | 2,138,241.16 | 1,566,645.02 |
| 资产处置收益 | - | 884.96 | - | - |
| 资产减值损失(新) | -3,493,183.16 | -4,842,406.63 | -27,488,316.82 | -14,586,352.55 |
| 信用减值损失(新) | -2,234,053.52 | -22,781,471.24 | -10,047,140.26 | -7,901,776.69 |
| 其他收益 | 419,707.46 | 1,323,007.63 | 997,728.85 | 497,882.1 |
| 四、营业利润 | 7,290,434.57 | 44,244,477.86 | 38,887,214.29 | 30,649,080.38 |
| 加:营业外收入 | 2,523.33 | 439,255.39 | 43,255.17 | 23,772.75 |
| 减:营业外支出 | 29,540.08 | 521,847.98 | 210,441.91 | 122,299.33 |
| 五、利润总额 | 7,263,417.82 | 44,161,885.27 | 38,720,027.55 | 30,550,553.8 |
| 减:所得税费用 | 620,693.26 | 3,473,948.02 | 6,045,796.48 | 5,067,147.95 |
| 六、净利润 | 6,642,724.56 | 40,687,937.25 | 32,674,231.07 | 25,483,405.85 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 6,642,724.56 | 40,687,937.25 | 32,674,231.07 | 25,483,405.85 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 6,642,724.56 | 40,687,937.25 | 32,674,231.07 | 25,483,405.85 |
| 扣除非经常损益后的净利润 | 5,453,353.07 | 32,785,841.63 | 30,420,688.49 | 24,058,720.87 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.11 | 0.09 | 0.07 |
| (二)稀释每股收益 | 0.02 | 0.11 | 0.09 | 0.07 |
| 八、其他综合收益 | - | 40,319.46 | - | - |
| 归属于母公司股东的其他综合收益 | - | 40,319.46 | - | - |
| 九、综合收益总额 | 6,642,724.56 | 40,728,256.71 | 32,674,231.07 | 25,483,405.85 |
| 归属于母公司股东的综合收益总额 | 6,642,724.56 | 40,728,256.71 | 32,674,231.07 | 25,483,405.85 |
| 公告日期 | 2026-04-25 | 2026-03-28 | 2025-10-28 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |